{Reference Type}: Case Reports
{Title}: Efficacy of methylphenidate treatment in childhood myotonic dystrophy type 1 and comorbid attention deficit hyperactivity disorder: A case report using eye tracking assessment.
{Author}: Sweere DJJ;Hendriksen JGM;Jeroen Vermeulen R;Klinkenberg S;
{Journal}: Brain Dev
{Volume}: 46
{Issue}: 2
{Year}: 2024 Feb 24
{Factor}: 2.272
{DOI}: 10.1016/j.braindev.2023.11.004
{Abstract}: <B>BACKGROUND: </B>Despite the increased prevalence of comorbid attention deficit hyperactivity disorder (ADHD) in children with myotonic dystrophy type 1, the effects of methylphenidate treatment on associated cognitive deficits in this population is not yet investigated.<BR><B>METHODS: </B>We describe a case study of an eleven-year-old male patient with myotonic dystrophy type 1 and comorbid ADHD that was treated with methylphenidate in a twice daily regime (0.60 mg/kg/day). Positive effects on learning and cognition were reported by the parents and teachers. No negative side effects were reported. Sequential neuropsychological assessments before and 45 minutes after methylphenidate intake were conducted to quantify the cognitive effects of methylphenidate treatment. Significant improvements in regulation of attention were behaviorally observed and were quantified using eye tracking technology.<BR><B>CONCLUSIONS: </B>We conclude that methylphenidate may be an effective treatment for ADHD-related cognitive deficits and learning difficulties in children with myotonic dystrophy type 1 which merits further research.